Phosphodiesterase 9: Insights from protein structure and role in therapeutics

Life Sciences

Volumn 106, Issue 1-2, 2014, Pages 1-11

  Singh, Nivedita ^a   Patra, Sanjukta ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY GUWAHATI   (India)

Author keywords

BAY 73 9961; Brain; cGMP; PDE9A; PF 04447943; Phosphodiesterase

Indexed keywords

CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 9A; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BIPOLAR DISORDER; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; DOWN SYNDROME; DYSLIPIDEMIA; ENZYME ACTIVE SITE; HYDROGEN BOND; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC SYNDROME X; NERVE CELL PLASTICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN FAMILY; PROTEIN STRUCTURE; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; START CODON; STEM CELL; SYNAPTIC TRANSMISSION;

BAY 73-9961; BRAIN; CGMP; PDE9A; PF-04447943; PHOSPHODIESTERASE;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ANIMALS; BRAIN DISEASES; HUMANS; MEMBRANE PROTEINS; PHOSPHODIESTERASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84901690469     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2014.04.007     Document Type: Review

References (91)

1. A.F. Abdel-Magid PDE10 inhibitors as potential treatment for schizophrenia ACS Med Chem 4 2 2013 161 162
2. M. Ahmad, Y.H.A. Abdel-Wahab, R. Tate, P.R. Flatt, N.J. Pyne, and B.L. Furman Effect of type-selective inhibitors on cyclic nucleotide phosphodiesterase activity and insulin secretion in the clonal insulin secreting cell line BRIN-BD11 Br J Pharmacol 129 6 2000 1228 1234 (Pubitemid 30153980)
3. S.G. Andreeva, P. Dikkes, P.M. Epstein, and P.A. Rosenberg Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain J Neurosci 21 22 2001 9068 9076 (Pubitemid 33054868)
4. Bell AS, Di Ninno MP, Palmer MJ, Visser MS. PDE9 inhibitors for treating type 2 diabetes, metabolic syndrome and cardiovascular disease. US Pat App Pub (Pub No.- US2004/0220186A1).
5. A.T. Bender, and J.A. Beavo Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use Pharmacol Rev 58 2006 488 520 (Pubitemid 44394910)
6. A.T. Bender, C.L. Ostenson, E.H. Wang, and J.A. Beavo Selective up-regulation of PDE1B2 upon monocyte-to-macrophage differentiation Proc Natl Acad Sci U S A 102 2 2004 497 502 (Pubitemid 40116795)
7. Black SC, Gibbs EM, McNeish JD. Phosphodiesterase 9 inhibition as treatement for obesity related conditions. US Pat App Pub (Pub. No.- US2008/0282364 A1).
8. F.G. Boess, M. Hendrix, F.V. Staay, C. Erb, R. Schreiber, and W.V. Staveren et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance Neuropharmacol 47 2004 1081 1092 (Pubitemid 39535847)
9. T. Braumann, C. Erneux, G. Petridis, W.D. Stohrer, and B. Jastorff Hydrolysis of cyclic nucleotides by a purified cGMP-stimulated phosphodiesterase: structural requirements for hydrolysis Biochim Biophys Acta 871 2 1986 199 206 (Pubitemid 16085079)
10. K.B. Cahill, J.H. Quade, K.L. Carleton, and R.H. Cote Identification of amino acid residues responsible for the selectivity of tadalafil binding to two closely related phosphodiesterases, PDE5 and PDE6 J Biol Chem 287 49 2012 41406 41416
11. G.L. Card, B.P. England, Y. Suzuki, D. Fong, B. Powell, and B. Lee et al. Structural basis for the activity of drugs that inhibit phosphodiesterases Structure 12 2004 2233 2247 (Pubitemid 39593200)
12. T. Castaño, H. Wang, N.E. Campillo, S. Ballester, C. González-García, and J. Hernández et al. Synthesis, structural analysis, and biological evaluation of Thioxoquinazoline derivatives as phosphodiesterase 7 inhibitors ChemMedChem 4 5 2009 866 876
13. M.M. Claffey, C.J. Helal, P.R. Verhoest, Z. Kang, K.S. Fors, and S. Jung et al. Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors J Med Chem 55 21 2012 9055 9068
14. M. Conti, and J. Beavo Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling Annu Rev Biochem 76 2007 481 511
15. F.H. da Silva, M.N. Pereira, C.F. Franco-Penteado, G.D. Nucci, E. Antunes, and M.A. Claudino Phosphodiesterase-9 (PDE9) inhibition with BAY 73-6691 increases corpus cavernosum relaxations mediated by nitric oxide-cyclic GMP pathway in mice Int J Impot Res 25 2013 69 73
16. A. Das, L. Xi, and R.C. Kukreja Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling J Biol Chem 280 13 2005 12944 12955
17. J. de Vente cGMP: a second messenger for acetylcholine in the brain? Neurochem Int 45 6 2004 799 812 (Pubitemid 39108052)
18. M.P. Deninno, M. Andrews, A.S. Bell, Y. Chen, C. Eller-Zarbo, and N. Eshelby et al. The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycaemic agents Bioorg Med Chem 19 9 2009 2537 2541
19. T.R. Dunkern, and A. Hatzelmann Characterization of inhibitors of phosphodiesterase 1C on a human cellular system FEBS J 274 18 2007 4812 4824 (Pubitemid 47353125)
20. S. Erceg, P. Monfort, M. Hernandez-Viadel, M. Llansola, and C. Montoliu Vicente Felipo Restoration of learning ability in hyperammonemic rats by increasing extracellular cGMP in brain Brain Res 1036 2 2005 115 121 (Pubitemid 40255850)
21. O.V. Evgenov, C.J. Busch, N.V. Evgenov, R. Liu, B. Petersen, and G.E. Falkowski et al. Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension Am J Physiol Lung Cell Mol Physiol 290 2006 L723 L729
22. D.A. Fisher, J.F. Smith, J.S. Pillar, S.H.S. Denis, and J.B. Cheng Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase J Biol Chem 273 19 1998 15559 15564 (Pubitemid 28298168)
23. S.H. Francis, M.A. Blount, and J.D. Corbin Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions Physiol Rev 91 2011 651 690
24. A. Friebe, and D. Koesling Regulation of nitric oxide-sensitive guanylyl cyclase Circ Res 93 2 2003 96 105 (Pubitemid 36919696)
25. D.A. Fryburg, and E.M. Gibbs Treatment of insulin resistance syndrom and type 2 Diabetes with PDE9 inhibitors. App Pub (Pub No.- US2005/0070557 A1) 2005
26. I. Goldstein, T.F. Lue, H. Padma-Nathan, R.C. Rosen, W.D. Steers, and P. Wicker Oral sildenafil in the treatment of erectile dysfunction. Sildenafil study group N Engl J Med 338 20 1998 1397 1404 (Pubitemid 28221980)
27. U. Gomez-Pinedo, R. Rodrigo, O. Cauli, A. Cabrera-Pastor, S. Herraiz, and J.M. Garcia-Verdugo et al. cGMP modulates stem cells differentiation to neurons in brain in vivo pathological implications BMC Pharmacol 11 Suppl. 1 2011 O29
28. R.L. Goncalves, C. Lugnier, T. Keravis, M.J. Lopes, F.A. Fantini, and M. Schmitt et al. The flavonoid dioclein is a selective inhibitor of cyclic nucleotide phosphodiesterase type 1 (PDE1) and a cGMP-dependent protein kinase (PKG) vasorelaxant in human vascular tissue Eur J Pharmacol 620 2009 78 83
29. M. Guipponi, H.S. Scott, J. Kudoh, K. Kawasaki, K. Shibuya, and A. Shintani et al. Identification and characterization of a novel cyclic nucleotide phosphodiesterase gene (PDE9A) that maps to 21q223: alternative splicing of mRNA transcripts, genomic structure and sequence Hum Genet 103 1998 386 392 (Pubitemid 28542945)
30. D.M.G. Halpin ABCD of the phosphodiesterase family: interaction and differential activity in COPD Int J Chron Obstruct Pulmon Dis 3 4 2008 543 561
31. N. Handa, M. Shirouzu, T. Terada, K. Omori, J. Kotera, and S. Yokoyama Crystal structure of the human phosphodiesterase 9a catalytic domain PDB Deposition 2007
32. J. Hou, J. Xu, M. Liu, R. Zhao, H.B. Luo, and H. Ke Structural asymmetry of phosphodiesterase-9, potential protonation of a glutamic acid, and role of the invariant glutamine PLoS One 6 2011 e18092
33. F. Hu, J. Ren, J. Zhang, W. Zhong, and M. Luo Natriuretic peptides block synaptic transmission by activating phosphodiesterase 2A and reducing presynaptic PKA activity Proc Natl Acad Sci U S A 109 43 2012 17681 17686
34. Q. Huai, H. Wang, W. Zhang, R.W. Colman, H. Robinson, and H. Ke Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding Proc Natl Acad Sci U S A 101 26 2004 9624 9629 (Pubitemid 38869286)
35. P.H. Hutson, E.N. Finger, B.C. Magliaro, S.M. Smith, A. Converso, and P.E. Sanderson et al. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1- (tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents Neuropharmacol 61 4 2011 665 676
36. Y.H. Jeon, Y.S. Heo, C.M. Kim, and Y.L. Hyun Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development Cell Mol Life Sci 62 2005 1198 1220 (Pubitemid 40880125)
37. X. Jiang, J. Li, M. Paskind, and P.M. Epstein Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells Proc Natl Acad Sci U S A 93 1996 11236 11241 (Pubitemid 26333147)
38. D.A. Kass, H.C. Champion, and J.A. Beavo Phosphodiesterase type 5: expanding roles in cardiovascular regulation Circ Res 101 11 2007 1084 1095 (Pubitemid 350146434)
39. H. Ke, and H. Wang Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity Curr Top Med Chem 7 4 2007 391 403 (Pubitemid 46358652)
40. H. Ke, H. Wang, and M. Ye Structural insight into the substrate specificity of phosphodiesterases phosphodiesterases as drug targets Handb Exp Pharmacol 204 2011 121 134
41. T. Keravis, and C. Lugnier Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments Br J Pharmacol 165 5 2012 1288 1305
42. 1-adrenergic antagonist Cardiovasc Drug Rev 17 4 1999 374 383 (Pubitemid 30161294)
43. E. Kim, and J.M. Park Identification of novel target proteins of cyclic GMP signaling pathways using chemical proteomics J Biochem Mol Biol 36 3 2003 299 304 (Pubitemid 36890829)
44. R.J. Kleiman, D.S. Chapin, C. Christoffersen, J. Freeman, K.R. Fonseca, and K.F. Geoghegan et al. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo J Pharmacol Exp Ther 34 2 2012 396 409
45. T. Kleppisch Phosphodiesterases in the central nervous system Handb Exp Pharmacol 191 2009 71 92
46. K.S. Kroker, G. Rast, R. Giovannini, A. Marti, C. Dorner-Ciossek, and H. Rosenbrock Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP Neuropharmacol 62 2012 1964 1974
47. S. Liu, M.N. Mansour, K.S. Dillman, J.R. Perez, D.E. Danley, and P.A. Aeed et al. Structural basis for the catalytic mechanism of human phosphodiesterase 9 Proc Natl Acad Sci U S A 105 36 2008 13309 13314
48. K.A. Lucas, G.M. Pitari, S. Kazerounian, I. Ruiz-Stewart, J. Park, and S. Schulz et al. Guanylyl cyclases and signaling by cyclic GMP Pharmacol Rev 52 3 2000 375 414
49. C. Lugnier Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents Pharmacol Ther 109 3 2006 366 398 (Pubitemid 43132818)
50. S.J. Mackenzie, and M.D. Houslay Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element- binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells Biochem J 347 2000 571 578 (Pubitemid 30229406)
51. A. Makhlouf, A. Kshirsagar, and C. Niederberger Phosphodiesterase 11: a brief review of structure, expression and function Int J Impot Res 18 6 2006 501 509 (Pubitemid 44658541)
52. A.E. Medina Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions Front Neurosci 5 2011 21
53. C. Mehats, C.B. Andersen, M. Filopanti, S.L. Jin, and M. Conti Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling Trends Endocrinol Metab 13 2002 29 35 (Pubitemid 36734013)
54. F. Meng, J. Hou, Y.X. Shao, P.Y. Wu, M. Huang, and X. Zhu et al. Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design J Med Chem 55 19 2012 8549 8558
55. A.M. Michie, M. Lobban, T. Muller, M.M. Harnett, and M.D. Houslay Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram Cell Signal 8 2 1996 97 110
56. L.I. Miguel, C.B. Almeida, F. Traina, A.A. Canalli, V.M. Dominical, and S.T.O. Saad et al. Inhibition of phosphodiesterase 9A reduces cytokine-stimulated in vitro adhesion of neutrophils from sickle cell anemia individuals Inflamm Res 60 2011 633 642
57. F. Mullershausen, M. Russwurm, D. Koesling, and A. Friebe In vivo reconstitution of the negative feedback in nitric oxide/cGMP signaling: role of phosphodiesterase type 5 phosphorylation Mol Biol Cell 15 9 2004 4023 4030 (Pubitemid 39122008)
58. T. Nicholas, Y. Park, H.W. Choo, A. Plotka, W. Martin, and D. Martin et al. Pharmacokinetic and safety interactions between a novel PDE9 inhibitor, PF-04447943, and donepezil in healthy volunteers. Alzheimer's & Dementia J Alzheimer's Assoc 7 4 2011 S786
59. P. Oeckl, P. Steinacker, S. Lehnert, S. Jesse, Kretzschmar, and A.C. Ludolph et al. CSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosis PLoS One 7 3 2012 e32664
60. K. Omori, and J. Kotera Overview of PDEs and their regulation Circ Res 100 3 2007 309 327
61. I. Paterniti, E. Mazzon, C. Gil, D. Impellizzeri, V. Palomo, and M. Redondo et al. PDE 7 inhibitors: new potential drugs for the therapy of spinal cord injury PLoS One 6 1 2011 e15937
62. K.F. Rabe Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease Br J Pharmacol 163 1 2011 53 67
63. Y.J. Rao, and L. Xi Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts Acta Pharmacol Sin 30 1 2009 1 24
64. O.A. Reneerkens, K. Rutten, H.W. Steinbusch, A. Blokland, and J. Prickaerts Selective phosphodiesterase inhibitors: a promising target for cognition enhancement Psychopharmacol (Berl) 202 1-3 2009 419 443
65. C. Rentero, and P. Puigdomènech Specific use of start codons and cellular localization of splice variants of human phosphodiesterase 9A gene BMC Mol Biol 7 2006 39
66. C. Rentero, A. Monfort, and P. Puigdomènech Identification and distribution of different mRNA variants produced by differential splicing in the human phosphodiesterase 9A gene Biochem Biophys Res Commun 301 3 2003 686 692 (Pubitemid 36268946)
67. T.R. Russell, W.L. Terasaki, and M.M. Appleman Separate phosphodiesterases for the hydrolysis of cyclic adenosine 3′, 5′-monophosphate and cyclic guanosine 3′, 5′-monophosphate in rat liver J Biol Chem 248 4 1973 1334 1340
68. R. Saravani, F. Karami-Tehrani, M. Hashemi, M. Aghaei, and R. Edalat Inhibition of phosphodiestrase 9 induces cGMP accumulation and apoptosis in human breast cancer cell lines, MCF-7 and MDA-MB-468 Cell Prolif 45 3 2012 199 206
69. G. Schett, V.S. Sloan, R.M. Stevens, and P. Schafer Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases Ther Adv Musculoskelet Dis 2 5 2010 271 278
70. E. Schwam, R. Evans, T. Nicholas, R. Chew, W. Davidson, and D. Ambrose PF-04447943: a phase II controlled clinical trial of a selective PDE9A inhibitor in Alzheimer's disease Alzheimer's & Dementia J Alzheimer's Assoc 7 4 2011 S695
71. M. Shimizu-Albergine, E. Patrucco, L. Tsai, J.S. Campbell, and J.A. Beavo Role of phosphodiesterase 8A (PDE8A) in lipid metabolism in the liver FASEB J 22 2008 90 94
72. S.H. Soderling, S.J. Bayuga, and J.A. Beavo Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases J Biol Chem 273 25 1998 15553 15558 (Pubitemid 28298167)
73. J. Surapisitchat, K.I. Jeon, C. Yan, and J.A. Beavo Differential regulation of endothelial cell permeability by cGMP via phosphodiesterases 2 and 3 Circ Res 101 8 2007 811 818 (Pubitemid 350287196)
74. R.J. Tedford, A.R. Hemnes, S.D. Russell, I.S. Wittstein, M. Mahmud, and A.L. Zaiman et al. PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support Circ Heart Fail 1 4 2008 213 219
75. H.L. Trong, N. Beier, W.K. Sonnenburg, S.D. Stroop, K.A. Walsh, and J.A. Beavo et al. Amino acid sequence of the cyclic GMP stimulated cyclic nucleotide phosphodiesterase from bovine heart Biochemistry 29 44 1990 10280 10288 (Pubitemid 20384535)
76. F.J. Van der Staay, K. Rutten, L. Bärfacker, J. Devry, C. Erb, and H. Heckroth et al. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents Neuropharmacol 55 5 2008 908 918
77. A.G. Vang, S.Z. Ben-Sasson, H. Dong, B. Kream, M.P. DeNinno, and M.M. Claffey et al. PDE8 regulates rapid Teff cell adhesion and proliferation independent of ICER PLoS One 5 8 2010 e12011
78. J.D. Vardigan, A. Converso, P.H. Hutson, and J.M. Uslaner The selective phosphodiesterase 9(PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task J Neurogenet 25 4 2011 120 126
79. P.R. Verhoest, C. Proulx-Lafrance, M. Corman, L. Chenard, C.J. Helal, and X. Hou et al. Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy J Med Chem 52 24 2009 7946 7949
80. P.R. Verhoest, K.R. Fonseca, X. Hou, C. Proulx-Lafrance, M. Corman, and C.J. Helal et al. Design and discovery of 6((3S,4S)4-Methyl-1-(pyrimidin-2- ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro2Hpyran-4-yl)-1,5-dihydro4Hpyrazolo(3,4d) pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders J Med Chem 55 21 2012 9045 9054
81. P. Wang, P. Wu, R.W. Egan, and M.M. Billah Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5) differential tissue distribution and subcellular localization of PDE9A variants Gene 18 314 2003 15 27 (Pubitemid 37186915)
82. H. Wang, Y. Liu, Q. Huai, J. Cai, R. Zoraghi, and S.H. Francis et al. Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development J Biol Chem 281 30 2006 21469 21479 (Pubitemid 44115485)
83. H. Wang, Y. Liu, J. Hou, M. Zheng, H. Robinson, and H. Ke Structural insight into substrate specificity of phosphodiesterase 10 Proc Natl Acad Sci U S A 104 14 2007 5782 5787 (Pubitemid 47175611)
84. H. Wang, X. Luo, M. Ye, J. Hou, H. Robinson, and H. Ke Insight into binding of phosphodiesterase-9A selective inhibitors by crystal structures and mutagenesis J Med Chem 53 4 2010 1726 1731
85. D. Westermann, P.M. Becher, D. Lindner, K. Savvatis, Y. Xia, and M. Fröhlich et al. Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo Basic Res Cardiol 107 6 2012 308
86. M. Witzenrath, B. Gutbier, B. Schmeck, H. Tenor, J. Seybold, and R. Kuelzer et al. Phosphodiesterase 2 inhibition diminished acute lung injury in murine pneumococcal pneumonia Crit Care Med 37 2 2009 584 590
87. F. Wunder, A. Tersteegen, A. Rebmann, C. Erb, T. Fahrig, and M. Hendrix Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line Mol Pharmacol 68 6 2005 1775 1781 (Pubitemid 41654360)
88. F. Wunder, M.J. Gnoth, A. Geerts, and D. Barufe A novel PDE2A reporter cell line: characterization of the cellular activity of PDE inhibitors Mol Pharm 6 1 2009 326 336
89. I. Yougbare, C. Morin, F.Y. Senouvo, C. Sirois, R. Albadine, and C. Lugnier et al. NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues Am J Physiol Lung Cell Mol Physiol 301 4 2011 L441 L450
90. K.Y. Zhang, G.L. Card, Y. Suzuki, D.R. Artis, D. Fong, and S. Gillette et al. A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases Mol Cell 15 2 2004 279 286 (Pubitemid 38950974)
91. R. Zoraghi, S.H. Francis, and J.D. Corbin Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors Biochemistry 46 47 2007 13554 13556